A dietary survey of patients with irritable bowel syndrome

Hayes, P.; Corish, Clare; O’Mahony, Edmond; Quigley, Eamonn Martin

doi:10.1111/jhn.12114

Cited by 118 publications

(129 citation statements)

References 59 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…While true food allergies are considered uncommon in IBS [1], food intolerances or sensitivities are frequently reported [35]. In a general population study, only 19.4% (95% confidence interval [CI], 11.4-27.4%) of patients who believed they had a food intolerance had a positive reaction during a blinded food challenge [36].…”

Section: Role Of Diet In Ibsmentioning

confidence: 99%

“…Over the last few years, foodrelated symptoms have received increased attention, and emerging evidence supports the evaluation of diet modification for patients with IBS [37]. In fact, approximately 90% of patients with IBS restrict their diet to prevent or improve GI symptoms [35]. One potential mechanism for the important role diet may play in IBS involves endocrine cells localized to the GI lumen.…”

Section: Role Of Diet In Ibsmentioning

confidence: 99%

See 1 more Smart Citation

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Harris

Baffy

2017

Postgraduate Medicine

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS), which is characterized by recurrent abdominal pain and disordered bowel habits, is one of the most common functional bowel disorders. IBS is a substantial burden on both patient health-related quality of life and healthcare costs. Several pathophysiologic mechanisms have been postulated for the occurrence of IBS, including altered gastrointestinal motility, visceral hypersensitivity, changes in gut permeability, immune activation, gut-brain dysregulation, central nervous system dysfunction, and changes in the gut microbiota. Of note, both qualitative and quantitative differences have been observed in the gut microbiota of a population with IBS versus a healthy population. Because of the substantial interest in the gut microbiota and its role as a therapeutic target in IBS, this article provides an overview of specific interventions with the potential to modulate the gut microbiota in IBS, including elimination diets, prebiotics, probiotics, synbiotics, and nonsystemic antibiotics. Although probiotics and synbiotics are generally well tolerated, differences in the composition and concentration of different bacterial species and inclusion or exclusion of prebiotic components varies widely across studies and has prevented strong recommendations on their use in IBS. For nonsystemic antibiotics, rifaximin is indicated in the United States for the treatment of IBS with diarrhea in adults and has been shown to be efficacious and well tolerated in well-designed clinical trials. Overall, more consistent evidence is needed regarding the efficacy and safety of elimination diets, prebiotics, probiotics, and synbiotics for the treatment of patients with IBS. Furthermore, additional well-designed studies are needed that examine alterations in the gut microbiota that occur with these interventions and their potential associations with clinical symptoms of IBS. ARTICLE HISTORY

show abstract

Section: Role Of Diet In Ibsmentioning

confidence: 99%

Section: Role Of Diet In Ibsmentioning

confidence: 99%

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Harris

Baffy

2017

Postgraduate Medicine

View full text Add to dashboard Cite

show abstract

“…A large number of IBS patients consider their symptoms related to food, and two-thirds of IBS patients report restricting their diets. [19][20][21][22][23] Many different dietary approaches for the management of the IBS symptoms have been tried over the years. 24 There are many mechanisms by which food may act on the gut to cause symptoms of IBS.…”

Section: Diet and Intestinal Microbiotamentioning

confidence: 99%

“…39 A substantial number of people with IBS report that their symptoms are associated with fatty food, and that they frequently avoid fatty foods to alleviate the symptoms. 19,21,39,40 In people with IBS, the lipid-induced inhibition of gut-propulsive motility is up-regulated, and the colonic hypersensitivity in response to the duodenal lipid infusion is exacerbated. 39,41,42 These effects may be associated with various IBS symptoms.…”

Section: Diet and Intestinal Microbiotamentioning

confidence: 99%

Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders

Lee

Choi

Ryu

et al. 2017

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Functional bowel disorders (FBDs) are functional gastrointestinal disorders with symptoms attributable to the middle or lower gastrointestinal tract. These include irritable bowel syndrome, functional bloating, functional constipation, functional diarrhea, and unspecified FBD. Increasing evidence has emerged of late that intestinal microbiota is involved in the pathogenesis of FBDs. In this review, the therapeutic benefits and future perspectives of the currently available strategies for modifying the gut microbiota in FBDs are described, focusing primarily on irritable bowel syndrome and functional constipation.

show abstract

“…1,2 Roughly two thirds of patients with IBS associate the onset or worsening of their symptoms with food intake. [3][4][5][6] To date, the greatest attention has focused on diets excluding FODMAPs (fermentable oligo-di-monosaccharides and polyols) or gluten in treatment of IBS symptoms. 7,8 Many commercially available foods and beverages contain artificial sweeteners (AS), sometimes unbeknownst to the consumer.…”

Section: Introductionmentioning

confidence: 99%

Artificial Sweeteners: A Systematic Review and Primer for Gastroenterologists

Spencer

Gupta

Dam

et al. 2016

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Artificial sweeteners (AS) are ubiquitous in food and beverage products, yet little is known about their effects on the gastrointestinal (GI) tract, and whether they play a role in the development of GI symptoms, especially in patients with irritable bowel syndrome. Utilizing the PubMed and Embase databases, we conducted a search for articles on individual AS and each of these terms: fermentation, absorption, and GI tract. Standard protocols for a systematic review were followed. At the end of our search, we found a total of 617 eligible papers, 26 of which were included. Overall, there is limited medical literature available on this topic. The 2 main areas on which there is data to suggest that AS affect the GI tract include motility and the gut microbiome, though human data is lacking, and most of the currently available data is derived from in vivo studies. The effect on motility is mainly indirect via increased incretin secretion, though the clinical relevance of this finding is unknown as the downstream effect on motility was not studied. The specific effects of AS on the microbiome have been conflicting and the available studies have been heterogeneous in terms of the population studied and both the AS and doses evaluated. Further research is needed to assess whether AS could be a potential cause of GI symptoms. This is especially pertinent in patients with irritable bowel syndrome, a population in whom dietary interventions are routinely utilized as a management strategy.

show abstract

A dietary survey of patients with irritable bowel syndrome

Cited by 118 publications

References 59 publications

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders

Artificial Sweeteners: A Systematic Review and Primer for Gastroenterologists

Contact Info

Product

Resources

About